| Application no. and date | 18179301.9 (espacenet) (Federated) (European Patent Register), 20091221 | | Patent/reg. no. and date | DK/EP 3409274, 20191120 | | Publication date | 20181205 | | Priority no. and date | US 139672 P, 20081222, US 218530 P, 20090619, US 246715 P, 20090929 | | EP pub. no. and date |
EP 3409274 20181205 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | V1911-059-DK | | Inventor | Dumortier, Thomas, Novartis Pharma AG Postfach
4002 Basel, CH,
David, Olivier, Novartis Pharma AG Postfach
4002 Basel, CH,
Looby, Michael, Novartis Pharma AG Postfach
4002 Basel, CH,
Schmouder, Robert, One Health Plaza
East Hanover, New Jersey 07936, US | | Representative | NORDIC PATENT SERVICE A/S, Bredgade 30, 1260 København K | | Opponent | | | IPC Class | A61K 31/135 (2006.01) , A61K 31/137 (2006.01) , A61K 31/138 (2006.01) , A61K 31/661 (2006.01) , A61P 37/00 (2006.01) , A61P 37/06 (2006.01) | | Title | DOSERINGSSKEMA FOR EN S1P-RECEPTORAGONIST | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | CA 2020 00052 | | Status | Ophævet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
